NASDAQ · Biotechnology · USD
Quantum BioPharma Ltd. (QNTM) Stock Analysis
Quantum BioPharma Ltd. (QNTM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
QNTM Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.45
- Previous Close
- $2.43
- Day's Range
- 2.39–2.48
- 52-Week Range
- 2.07–14.86
- Volume
- 90.34K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.38
Valuation
- Market Cap
- $15.43M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.98
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$26.18M
- Shares Outstanding
- 6.43M
- 1-Year Return
- −83.64%
Dividend and dates
- Avg Volume
- 208.36K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, QNTM closed at $2.40, −83.64% over 1 year.
Quantum BioPharma Ltd. (QNTM) has a market capitalization of $15.43M.
In fiscal 2025, QNTM reported revenue of $0.00.
QNTM Stock Return by Calendar Year
Quantum BioPharma Ltd. (QNTM) return since Jun 2018: what $10,000 became
- 1 year
- $10,000 $1,636
- −83.64%
- 5 years
- $10,000 $248
- −97.52%
- Since Jun 2018
- $10,000 $21
- −99.79%
If you had invested $10,000 in Quantum BioPharma Ltd. (QNTM) at the close on June 8, 2018, the earliest close on record here, it would have been worth $21 at the close on October 21, 2026: −99.79% in total, −52.03% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −67.12% |
| 2025 | +98.37% |
| 2024 | −93.85% |
| 2023 | +16.75% |
| 2022 | −22.75% |
| 2021 | −34.62% |
| 2020 | −71.27% |
| 2019 | −87.38% |
| 2018 (partial year) | +148.84% |
As of October 21, 2026.
QNTM Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$26.18M | — |
| 2024 | $0.00 | −$14.20M | — |
| 2023 | $0.00 | −$17.90M | — |
| 2022 | $0.00 | −$23.61M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$15.32M | −$26.18M | — |
| 2024 | $0.00 | — | −$15.88M | −$14.20M | — |
| 2023 | $0.00 | — | −$19.57M | −$17.90M | — |
| 2022 | $0.00 | — | −$27.43M | −$23.61M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Quantum BioPharma (QNTM) Featured in Men's Fitness Article Examining Unbuzzd Clinical Trial Results
YahooQuantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
MarketBeatWorld Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
YahooQuantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
YahooQuantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
YahooQuantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Yahoo
All 20 articles ↓Show fewer ↑
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
YahooEXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
BenzingaIBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
YahooQuantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing
YahooQuantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
YahooQuantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO
BenzingaQuantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
YahooRodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
YahooQuantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
YahooQuantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
YahooQuantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
YahooQuantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
YahooReported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing
BenzingaQuantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B